BioInvent International (STO:BINV)24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by ...
Moderna and Merck's combination therapy for skin cancer helped reduce risk of cancer spreading to another part of the body ...
BioInvent International (STO:BINV)24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by ...
NASA has enabled scientists to study the impact of microgravity on drug development for decades, beginning with the Space Shuttle. This work accelerated in the 2010s, with the completion of the ...
Biotech dealmaking is on pace for a bumper year in 2026, with large drugmakers on an acquisition spree to boost their pipelines ahead of upcoming patent losses.
Preliminary results from a preclinical study demonstrated statistically significant increase in MHC-I expression following ...
Preview ASCO 2026 late-breaking cancer trials—from TNBC ADC survival gains to lung, liver, prostate and myeloma readouts ...
NHS rolls out “one minute” immunotherapy jab NHS England announced that it was rolling out a new injectable form of the ...
Precigen's PAPZIMEOS wins early FDA approval with rapid insurer/physician uptake, a strong growth outlook, and improving EPS.
Bank of America Global Healthcare Conference 2026 May 13, 2026 6:40 PM EDTCompany ParticipantsBalaji Prasad - Chief ...
Biopharma mergers and acquisitions have surged in early 2026, with $84 billion in deals announced in Q1, the strongest start since 2019. Large drugmakers are racing to acquire assets ahead of major ...
Will a hantavirus outbreak offset the regulatory risks weighing on Moderna stock? The path to recovery is far from certain.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results